Related Experiment Video
Updated: May 10, 2026
High-throughput Screening for Broad-spectrum Chemical Inhibitors of RNA Viruses
Published on: May 5, 2014
Discovery of Novel PTP1B Inhibitors by High-throughput Virtual Screening
Abhijit Debnath1, Anjna Rani1, Rupa Mazumder1
1Pharmacy Institute, Noida Institute of Engineering and Technology, 19 Knowledge Park-II, Institutional Area, Greater Noida, Uttar Pradesh, India.
Aims:
To Discover novel PTP1B inhibitors by high-throughput virtual screening.
Background:
Type 2 Diabetes is a significant global health concern. According to projections, the estimated number of individuals affected by the condition will reach 578 million by the year 2030 and is expected to further increase to 700 million deaths by 2045. Protein Tyrosine Phosphatase 1B is an enzymatic protein that has a negative regulatory effect on the pathways involved in insulin signaling. This regulatory action ultimately results in the development of insulin resistance and the subsequent elevation of glucose levels in the bloodstream. The proper functioning of insulin signaling is essential for maintaining glucose homeostasis, whereas the disruption of insulin signaling can result in the development of type 2 diabetes. Consequently, we sought to utilize PTP1B as a drug target in this investigation.
Objective:
The purpose of our study was to identify novel PTP1B inhibitors as a potential treatment for managing type 2 diabetes.
Methods:
To discover potent PTP1B inhibitors, we have screened the Maybridge HitDiscover database by SBVS. Top hits have been passed based on various drug-likeness rules, toxicity predictions, ADME assessment, Consensus Molecular docking, DFT, and 300 ns MD Simulations.
Results:
Compound RJC02059 has been identified with strong binding affinity at the active site of PTP1B along with drug-like properties, efficient ADME, low toxicity, and high stability.
Discussion:
Two compounds, demonstrated strong binding affinity, favorable drug-like properties, and stable interactions with PTP1B's active site throughout 200 ns MD simulations, with RJC02059 showing superior binding stability and persistent hydrogen bonding with catalytic residues. However, experimental validation through enzymatic assays and assessment of selectivity against related phosphatases, remain essential next steps to confirm therapeutic potential.
Conclusion:
The identified molecule could potentially manage T2DM effectively by inhibiting PTP1B, providing a promising avenue for therapeutic strategies.
More Related Videos
Related Concept Videos
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
01:29Pharmacogenomics: Identification of New Drug Targets